Latest Feature

Sequent Medical CEO Wilder bets on braids

Sequent Medical CEO Tom Wilder tells MassDevice.com why his company's MicroBraid technology is a key differentiator in its Web device for treating brain aneurysms and, potentially, other conditions.

Masimo's Kiani on 'good-enough innovation,' Medtronic, Apple and 25 years of pus

In this DeviceTalks preview, we catch up with Masimo CEO Joe Kiani to discuss new challenges facing the company and how medtech can break the cycle of the era of 'good-enough' innovation.

Medicare: Medical device companies paid out $200m to physicians last year

Medical device companies' aggregate spend on payment and other gifts to physicians was at least $200 million last year, according to the U.S. Health & Human Services Dept., but critics (and the agency itself) flag widespread problems with the Open Payments database.

Checking on Orange County's medtech climate with OCTANe's Matthew Jenusaitis

Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to MassDevice.com about OCTANe's 2014 Medical Device Investor Forum.

What's behind the slump in early-stage medtech investment?

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

FTC gives Medtronic, Covidien merger the green light

November 26, 2014 by Brian Johnson

The U.S. Federal Trade Commission has approved the pending $43 billion merger between Medtronic  and Covidien, according to regulatory filings.

Report: Medtronic readies $10B bond flotation for Covidien deal

MassDevice.com +3 | The top 3 medtech stories for November 26, 2014

November 26, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Neuromod wins CE Mark for tinnitus device

November 26, 2014 by Val Kennedy

Dublin-based Neuromod Devices says it won CE Mark approval in the European Union for its new multi-sensory device to treat tinnitus.

Neuromod wins CE Mark for tinnitus device

Dublin-based Neuromod Devices said it won CE Mark approval in the European Union for its new multi-sensory device to treat tinnitus, also known as "ear-ringing."

The product, mutebutton, is a handheld device that helps the brain distinguish between real and phantom noises through audio and tongue stimulation.

Stryker may bid for Smith & Nephew following 6-month no-bid period | The week in medtech M&A

November 26, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew

Will Stryker bid on Smith & Nephew this week?

November 24, 2014 by Brad Perriello

Hansen Medical's Magellan used in 1st robotic prostate embolization

November 26, 2014 by Mark Hollmer

Hansen Medical touts its Magellan robotic surgical device in the first successful robotic prostatic artery embolization in the U.S.

Hansen Medical's Magellan used in 1st robotic prostate embolization

X2 Biosystems raises $4m in debt offering

November 26, 2014 by Val Kennedy

Brain injury device developer X2 Biosystems sells approximately $4.2 million in debt and securities under a previously filed $9 million offering, according to a regulatory filing.

X2 Biosystems raises $4m in debt offering

Brain-injury device developer X2 Biosystems said it sold approximately $4.2 million worth of debt and securities under a previously filed $9 million offering.

Study: No benefit for mitral valve replacement alongside CABG

November 26, 2014 by Mark Hollmer

New data released by The Cardiothoracic Surgical Trials Network raises questions about adding mitral valve repair to coronary artery bypass graft procedures in patients with moderate ischemic mitral regurgitation.

Study: No benefit for mitral valve replacement alongside CABG

New clinical trial data challenges the usefulness of adding mitral valve repair to coronary artery bypass grafting in patients with moderate ischemic mitral regurgitation.

Philips wins FDA clearance for IQon Spectral CT system

November 26, 2014 by Val Kennedy

Royal Philips wins 510(k) clearance from the FDA for its IQon Spectral CT system for enhanced computed tomography imaging.

Philips wins FDA approval for IQon Spectral CT system

Royal Philips (NYSE:PHG) said it won 510(k) clearance from the FDA for its IQon Spectral CT system for enhanced computed tomography imaging.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp